TrialBlood advances2025

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Olivier Tournilhac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.